Evaxion Biotech AS (EVAX): מחיר למכירות

Evaxion Biotech A/S is developing an AI platform for vaccines while facing high scientific uncertainty and a lack of profitability. The enterprise value-to-revenue multiple helps assess the asset's market overvaluation, with the current metric standing at 3.10. Development relies on the outsourcing of computing and clinical trials. Financial stability is based on subsidies and occasional partner payments, as a stable commercial product is currently absent.

Evaxion Biotech A/S is investing colossal resources into the development of AI vaccines despite a lack of confirmed clinical efficacy. By analyzing the price-to-sales ratio, an investor can view the market capitalization in comparison to the business's actual revenue. This metric is calculated as the ratio of the current share price to revenue per share, measuring the premium for future growth. High values of this indicator signal that the asset is overvalued against a backdrop of high cash burn.